Related references
Note: Only part of the references are listed.Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model
Yuwei Liu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer
Liang Zhao et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
Justin Ferdinandus et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
Frederik L. Giesel et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
Clemens Kratochwil et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
Thomas Lindner et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Synthesis, chemical and biochemical characterization of Lu2O3 -iPSMA nanoparticles activated by neutron irradiation
A. Ancira-Cortez et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2020)
68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
Frederik L. Giesel et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention
Anastasia Loktev et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
Thomas Lindner et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
Anastasia Loktev et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Clinical translation of a PSMA inhibitor for 99mTc-based SPECT
Guillermina Ferro-Flores et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer
Sung Yeon Park et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Silver nanoparticles with antimicrobial activities against Streptococcus mutans and their cytotoxic effect
Mario Alberto Perez-Diaz et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2015)
Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque Imaging
Romana Meletta et al.
MOLECULES (2015)
Extended Structure Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycy1-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)
Koen Jansen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy
Elizabeth J. Hamson et al.
PROTEOMICS CLINICAL APPLICATIONS (2014)
Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase
Sarah E. Poplawski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
An experimental and theoretical investigation of Acenaphthene-5-boronic acid: Conformational study, NBO and NLO analysis, molecular structure and FT-IR, FT-Raman, NMR and UV spectra
Mehmet Karabacak et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2013)
Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold
Koen Jansen et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
99mTc-HYNIC-Gastrin Peptides: Assisted Coordination of 99mTc by Amino Acid Side Chains Results in Improved Performance Both In Vitro and In Vivo
Robert King et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
99Tc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours
E. von Guggenberg et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP
Thuy Tran et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Third generation radiopharmaceuticals for imaging and targeted therapy
Guillermina Ferro-Flores et al.
CURRENT PHARMACEUTICAL ANALYSIS (2006)
Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits
Armando Gonzalez-Vazquez et al.
APPLIED RADIATION AND ISOTOPES (2006)
Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity
CY Edosada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α
K Aertgeerts et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Structural overview of technetium compounds (1993-1999)
G Bandoli et al.
COORDINATION CHEMISTRY REVIEWS (2001)
99mTc-EDDA/HYNIC-TOC:: a new 99Tc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours:: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives
C Decristoforo et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)